

# Study of investigational odronextamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma




Primary Objective: evaluate the efficacy and safety of odronextamab vs SOC in patients with R/R aggressive B-NHL



PATIENTS WITH R/R AGGRESSIVE B-CELL NHL (N~216)

## OPEN LABEL INTERVENTION



## Primary Endpoint

Event-free survival<sup>a</sup>

## Secondary Endpoints

Progression-free survival  
Best overall response  
Patient-reported outcomes

### FIND OUT MORE

Scan here to find out more about this study at <https://clinicaltrials.gov/ct2/show/NCT-TBC>

This information is intended for investigators interested in open clinical trials.

Odronextamab is an investigational agent and has not been evaluated by any regulatory authority.

<sup>a</sup>Based on Independent Central Review (ICR).

ASCT, autologous stem cell transplant; B-NHL, B-cell non-Hodgkin lymphoma; CR, complete response; IV, intravenous; N, number of patients; PR, partial response; R, randomized; R/R, relapsed or refractory; SOC, standard of care.

# ODRONEXTAMAB

## An Investigational CD20xCD3 Bispecific Antibody

Simultaneously engages CD20 on malignant B cells and CD3 on cytotoxic T cells<sup>1</sup>

### SELECTED INCLUSION CRITERIA<sup>a</sup>



R/R aggressive B-NHL ≤ 1 year from start of first-line therapy



Measurable disease



ECOG PS 0 or 1



Adequate organ function status

### SELECTED EXCLUSION CRITERIA<sup>a</sup>



Primary CNS lymphoma



Significant CNS pathology



Evidence of any active infection

For more information, visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or please call [+353 (0)61 533 400 OR 844 REGN-MID].  
NCT  
<https://clinicaltrials.gov/ct2/show/NCT-TBC>

**This information is intended for investigators interested in open clinical trials.  
Odronextamab is an investigational agent and has not been evaluated by any regulatory authority.**

<sup>a</sup>Inclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on [clinicaltrials.gov](http://clinicaltrials.gov) for complete details.

CD, cluster of differentiation; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; R/R, relapsed or refractory.

Current per [clinicaltrials.gov](http://clinicaltrials.gov) as of Month day, 2023.

<sup>1</sup>Smith EJ et al. *Sci Rep.* 2015;5:17943

Veeva code November 2023.

©2023 Regeneron Pharmaceuticals, Inc. All rights reserved